nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ERBB3—gallbladder cancer	0.732	1	CbGaD
Dasatinib—SRMS—gall bladder—gallbladder cancer	0.00359	0.0436	CbGeAlD
Dasatinib—BMX—epithelium—gallbladder cancer	0.00194	0.0236	CbGeAlD
Dasatinib—STAT5B—epithelium—gallbladder cancer	0.00172	0.0209	CbGeAlD
Dasatinib—TEC—liver—gallbladder cancer	0.00167	0.0203	CbGeAlD
Dasatinib—STAT5B—pancreas—gallbladder cancer	0.00153	0.0186	CbGeAlD
Dasatinib—PDGFRA—gall bladder—gallbladder cancer	0.00153	0.0186	CbGeAlD
Dasatinib—BMPR1B—epithelium—gallbladder cancer	0.00138	0.0168	CbGeAlD
Dasatinib—EPHB1—liver—gallbladder cancer	0.00131	0.0159	CbGeAlD
Dasatinib—TEC—lymph node—gallbladder cancer	0.00128	0.0155	CbGeAlD
Dasatinib—KIT—gall bladder—gallbladder cancer	0.00122	0.0149	CbGeAlD
Dasatinib—PDGFRB—gall bladder—gallbladder cancer	0.0012	0.0145	CbGeAlD
Dasatinib—SIK2—liver—gallbladder cancer	0.00116	0.0141	CbGeAlD
Dasatinib—FRK—liver—gallbladder cancer	0.00113	0.0137	CbGeAlD
Dasatinib—RIPK2—epithelium—gallbladder cancer	0.00108	0.0131	CbGeAlD
Dasatinib—STK35—pancreas—gallbladder cancer	0.00105	0.0127	CbGeAlD
Dasatinib—CSK—pancreas—gallbladder cancer	0.00104	0.0126	CbGeAlD
Dasatinib—ERBB3—epithelium—gallbladder cancer	0.00104	0.0126	CbGeAlD
Dasatinib—EPHB1—lymph node—gallbladder cancer	0.001	0.0122	CbGeAlD
Dasatinib—STAT5B—liver—gallbladder cancer	0.000976	0.0118	CbGeAlD
Dasatinib—MAPK14—epithelium—gallbladder cancer	0.000964	0.0117	CbGeAlD
Dasatinib—SIK1—pancreas—gallbladder cancer	0.000941	0.0114	CbGeAlD
Dasatinib—ERBB3—pancreas—gallbladder cancer	0.000922	0.0112	CbGeAlD
Dasatinib—EPHB4—epithelium—gallbladder cancer	0.000914	0.0111	CbGeAlD
Dasatinib—JAK2—epithelium—gallbladder cancer	0.000908	0.011	CbGeAlD
Dasatinib—EPHA2—epithelium—gallbladder cancer	0.000897	0.0109	CbGeAlD
Dasatinib—SIK3—liver—gallbladder cancer	0.000877	0.0107	CbGeAlD
Dasatinib—BMX—lymph node—gallbladder cancer	0.000844	0.0103	CbGeAlD
Dasatinib—BLK—lymph node—gallbladder cancer	0.000835	0.0101	CbGeAlD
Dasatinib—ZAK—liver—gallbladder cancer	0.000816	0.0099	CbGeAlD
Dasatinib—EPHB4—pancreas—gallbladder cancer	0.000814	0.00988	CbGeAlD
Dasatinib—TXK—lymph node—gallbladder cancer	0.000799	0.0097	CbGeAlD
Dasatinib—EPHA2—pancreas—gallbladder cancer	0.000799	0.0097	CbGeAlD
Dasatinib—LYN—liver—gallbladder cancer	0.000794	0.00964	CbGeAlD
Dasatinib—MAP4K5—pancreas—gallbladder cancer	0.000779	0.00946	CbGeAlD
Dasatinib—BTK—liver—gallbladder cancer	0.000778	0.00945	CbGeAlD
Dasatinib—SRC—epithelium—gallbladder cancer	0.000777	0.00943	CbGeAlD
Dasatinib—TNK2—liver—gallbladder cancer	0.000767	0.00931	CbGeAlD
Dasatinib—STAT5B—lymph node—gallbladder cancer	0.000748	0.00908	CbGeAlD
Dasatinib—TESK1—liver—gallbladder cancer	0.000721	0.00875	CbGeAlD
Dasatinib—YES1—pancreas—gallbladder cancer	0.00072	0.00874	CbGeAlD
Dasatinib—STK36—liver—gallbladder cancer	0.00071	0.00861	CbGeAlD
Dasatinib—SRC—pancreas—gallbladder cancer	0.000692	0.0084	CbGeAlD
Dasatinib—EPHA3—lymph node—gallbladder cancer	0.000692	0.0084	CbGeAlD
Dasatinib—LIMK2—liver—gallbladder cancer	0.000686	0.00833	CbGeAlD
Dasatinib—SIK3—lymph node—gallbladder cancer	0.000673	0.00817	CbGeAlD
Dasatinib—STK35—liver—gallbladder cancer	0.000665	0.00807	CbGeAlD
Dasatinib—CSK—liver—gallbladder cancer	0.000661	0.00802	CbGeAlD
Dasatinib—HCK—liver—gallbladder cancer	0.000652	0.00792	CbGeAlD
Dasatinib—ABL2—liver—gallbladder cancer	0.000648	0.00787	CbGeAlD
Dasatinib—KIT—epithelium—gallbladder cancer	0.000634	0.00769	CbGeAlD
Dasatinib—ZAK—lymph node—gallbladder cancer	0.000625	0.00759	CbGeAlD
Dasatinib—PDGFRB—epithelium—gallbladder cancer	0.000619	0.00751	CbGeAlD
Dasatinib—RIPK2—liver—gallbladder cancer	0.000613	0.00744	CbGeAlD
Dasatinib—BMPR1B—lymph node—gallbladder cancer	0.0006	0.00728	CbGeAlD
Dasatinib—SIK1—liver—gallbladder cancer	0.000599	0.00727	CbGeAlD
Dasatinib—BTK—lymph node—gallbladder cancer	0.000597	0.00724	CbGeAlD
Dasatinib—TNK2—lymph node—gallbladder cancer	0.000588	0.00714	CbGeAlD
Dasatinib—ERBB3—liver—gallbladder cancer	0.000587	0.00712	CbGeAlD
Dasatinib—MAP3K2—liver—gallbladder cancer	0.000581	0.00706	CbGeAlD
Dasatinib—KIT—pancreas—gallbladder cancer	0.000564	0.00685	CbGeAlD
Dasatinib—TESK1—lymph node—gallbladder cancer	0.000553	0.00671	CbGeAlD
Dasatinib—PDGFRB—pancreas—gallbladder cancer	0.000551	0.00669	CbGeAlD
Dasatinib—MAPK14—liver—gallbladder cancer	0.000546	0.00663	CbGeAlD
Dasatinib—FGR—liver—gallbladder cancer	0.000544	0.00661	CbGeAlD
Dasatinib—LCK—liver—gallbladder cancer	0.000544	0.00661	CbGeAlD
Dasatinib—EPHB3—lymph node—gallbladder cancer	0.000544	0.00661	CbGeAlD
Dasatinib—STK36—lymph node—gallbladder cancer	0.000544	0.00661	CbGeAlD
Dasatinib—LIMK2—lymph node—gallbladder cancer	0.000526	0.00639	CbGeAlD
Dasatinib—FMO3—liver—gallbladder cancer	0.000526	0.00638	CbGeAlD
Dasatinib—EPHB4—liver—gallbladder cancer	0.000518	0.00629	CbGeAlD
Dasatinib—JAK2—liver—gallbladder cancer	0.000514	0.00624	CbGeAlD
Dasatinib—STK35—lymph node—gallbladder cancer	0.00051	0.00619	CbGeAlD
Dasatinib—EPHA2—liver—gallbladder cancer	0.000508	0.00617	CbGeAlD
Dasatinib—FYN—liver—gallbladder cancer	0.000507	0.00616	CbGeAlD
Dasatinib—CSK—lymph node—gallbladder cancer	0.000506	0.00615	CbGeAlD
Dasatinib—HCK—lymph node—gallbladder cancer	0.0005	0.00607	CbGeAlD
Dasatinib—ABL2—lymph node—gallbladder cancer	0.000497	0.00603	CbGeAlD
Dasatinib—MAP4K5—liver—gallbladder cancer	0.000496	0.00602	CbGeAlD
Dasatinib—MAP3K3—liver—gallbladder cancer	0.000496	0.00602	CbGeAlD
Dasatinib—ABL1—pancreas—gallbladder cancer	0.000491	0.00596	CbGeAlD
Dasatinib—RIPK2—lymph node—gallbladder cancer	0.00047	0.00571	CbGeAlD
Dasatinib—SIK1—lymph node—gallbladder cancer	0.000459	0.00557	CbGeAlD
Dasatinib—YES1—liver—gallbladder cancer	0.000458	0.00556	CbGeAlD
Dasatinib—EPHA4—lymph node—gallbladder cancer	0.000454	0.00552	CbGeAlD
Dasatinib—ERBB3—lymph node—gallbladder cancer	0.00045	0.00546	CbGeAlD
Dasatinib—PDGFRA—liver—gallbladder cancer	0.000449	0.00545	CbGeAlD
Dasatinib—MAP3K2—lymph node—gallbladder cancer	0.000446	0.00541	CbGeAlD
Dasatinib—SRC—liver—gallbladder cancer	0.00044	0.00535	CbGeAlD
Dasatinib—MAPK14—lymph node—gallbladder cancer	0.000419	0.00509	CbGeAlD
Dasatinib—FGR—lymph node—gallbladder cancer	0.000417	0.00507	CbGeAlD
Dasatinib—LCK—lymph node—gallbladder cancer	0.000417	0.00507	CbGeAlD
Dasatinib—MAP2K5—liver—gallbladder cancer	0.000405	0.00492	CbGeAlD
Dasatinib—FMO3—lymph node—gallbladder cancer	0.000403	0.00489	CbGeAlD
Dasatinib—EPHB4—lymph node—gallbladder cancer	0.000397	0.00482	CbGeAlD
Dasatinib—CSF1R—liver—gallbladder cancer	0.000395	0.0048	CbGeAlD
Dasatinib—JAK2—lymph node—gallbladder cancer	0.000394	0.00479	CbGeAlD
Dasatinib—EPHA2—lymph node—gallbladder cancer	0.00039	0.00473	CbGeAlD
Dasatinib—FYN—lymph node—gallbladder cancer	0.000389	0.00472	CbGeAlD
Dasatinib—MAP4K5—lymph node—gallbladder cancer	0.00038	0.00461	CbGeAlD
Dasatinib—MAP3K3—lymph node—gallbladder cancer	0.00038	0.00461	CbGeAlD
Dasatinib—EPHB6—lymph node—gallbladder cancer	0.000363	0.00441	CbGeAlD
Dasatinib—KIT—liver—gallbladder cancer	0.000359	0.00436	CbGeAlD
Dasatinib—YES1—lymph node—gallbladder cancer	0.000351	0.00426	CbGeAlD
Dasatinib—PDGFRB—liver—gallbladder cancer	0.000351	0.00426	CbGeAlD
Dasatinib—PDGFRA—lymph node—gallbladder cancer	0.000344	0.00418	CbGeAlD
Dasatinib—SRC—lymph node—gallbladder cancer	0.000338	0.0041	CbGeAlD
Dasatinib—CYP1A1—epithelium—gallbladder cancer	0.00033	0.00401	CbGeAlD
Dasatinib—ABL1—liver—gallbladder cancer	0.000313	0.00379	CbGeAlD
Dasatinib—MAP2K5—lymph node—gallbladder cancer	0.000311	0.00377	CbGeAlD
Dasatinib—CSF1R—lymph node—gallbladder cancer	0.000303	0.00368	CbGeAlD
Dasatinib—CYP3A5—pancreas—gallbladder cancer	0.000288	0.00349	CbGeAlD
Dasatinib—KIT—lymph node—gallbladder cancer	0.000275	0.00334	CbGeAlD
Dasatinib—PDGFRB—lymph node—gallbladder cancer	0.000269	0.00326	CbGeAlD
Dasatinib—CYP1B1—liver—gallbladder cancer	0.000265	0.00321	CbGeAlD
Dasatinib—ABL1—lymph node—gallbladder cancer	0.00024	0.00291	CbGeAlD
Dasatinib—CYP1B1—lymph node—gallbladder cancer	0.000203	0.00246	CbGeAlD
Dasatinib—ABCG2—liver—gallbladder cancer	0.000197	0.00239	CbGeAlD
Dasatinib—CYP1A2—liver—gallbladder cancer	0.00019	0.0023	CbGeAlD
Dasatinib—CYP1A1—liver—gallbladder cancer	0.000187	0.00227	CbGeAlD
Dasatinib—CYP3A5—liver—gallbladder cancer	0.000183	0.00222	CbGeAlD
Dasatinib—ABCB1—epithelium—gallbladder cancer	0.000172	0.00208	CbGeAlD
Dasatinib—ABCB1—pancreas—gallbladder cancer	0.000153	0.00185	CbGeAlD
Dasatinib—ABCG2—lymph node—gallbladder cancer	0.000151	0.00183	CbGeAlD
Dasatinib—CYP1A1—lymph node—gallbladder cancer	0.000143	0.00174	CbGeAlD
Dasatinib—CYP3A4—liver—gallbladder cancer	0.000137	0.00167	CbGeAlD
Dasatinib—ABCB1—liver—gallbladder cancer	9.72e-05	0.00118	CbGeAlD
Dasatinib—ABCB1—lymph node—gallbladder cancer	7.45e-05	0.000905	CbGeAlD
Dasatinib—FYN—Developmental Biology—HRAS—gallbladder cancer	9.32e-06	5.02e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—KRAS—gallbladder cancer	9.3e-06	5.01e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—HRAS—gallbladder cancer	9.29e-06	5e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—EGFR—gallbladder cancer	9.26e-06	4.99e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—HRAS—gallbladder cancer	9.24e-06	4.98e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB3—gallbladder cancer	9.21e-06	4.96e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—NRAS—gallbladder cancer	9.21e-06	4.96e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—gallbladder cancer	9.21e-06	4.96e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—KRAS—gallbladder cancer	9.2e-06	4.96e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—BCL2—gallbladder cancer	9.2e-06	4.95e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—ERBB2—gallbladder cancer	9.16e-06	4.93e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—HRAS—gallbladder cancer	9.14e-06	4.92e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—EGFR—gallbladder cancer	9.1e-06	4.9e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—HRAS—gallbladder cancer	9.1e-06	4.9e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	9.09e-06	4.89e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—gallbladder cancer	9.09e-06	4.89e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB3—gallbladder cancer	9.02e-06	4.86e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—BCL2—gallbladder cancer	9.01e-06	4.85e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—NRAS—gallbladder cancer	8.99e-06	4.84e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—HRAS—gallbladder cancer	8.97e-06	4.83e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—ERBB2—gallbladder cancer	8.97e-06	4.83e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—BCL2—gallbladder cancer	8.96e-06	4.83e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—HRAS—gallbladder cancer	8.96e-06	4.82e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—KRAS—gallbladder cancer	8.96e-06	4.82e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—ERBB2—gallbladder cancer	8.94e-06	4.81e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—NRAS—gallbladder cancer	8.93e-06	4.81e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB3—gallbladder cancer	8.88e-06	4.78e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—KRAS—gallbladder cancer	8.88e-06	4.78e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—BCL2—gallbladder cancer	8.87e-06	4.77e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—HRAS—gallbladder cancer	8.86e-06	4.77e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—HRAS—gallbladder cancer	8.8e-06	4.74e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—KRAS—gallbladder cancer	8.75e-06	4.71e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—ERBB2—gallbladder cancer	8.75e-06	4.71e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—ERBB2—gallbladder cancer	8.71e-06	4.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—HRAS—gallbladder cancer	8.69e-06	4.68e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—ERBB2—gallbladder cancer	8.64e-06	4.65e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—ERBB2—gallbladder cancer	8.61e-06	4.64e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—KRAS—gallbladder cancer	8.6e-06	4.63e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—EGFR—gallbladder cancer	8.55e-06	4.61e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—EGFR—gallbladder cancer	8.55e-06	4.61e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB4—gallbladder cancer	8.55e-06	4.6e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB3—gallbladder cancer	8.55e-06	4.6e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—HRAS—gallbladder cancer	8.54e-06	4.6e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—BCL2—gallbladder cancer	8.54e-06	4.6e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—EGFR—gallbladder cancer	8.53e-06	4.59e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB3—gallbladder cancer	8.44e-06	4.55e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—HRAS—gallbladder cancer	8.44e-06	4.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—BCL2—gallbladder cancer	8.43e-06	4.54e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—HRAS—gallbladder cancer	8.36e-06	4.5e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—HRAS—gallbladder cancer	8.32e-06	4.48e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—ERBB2—gallbladder cancer	8.29e-06	4.47e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—NRAS—gallbladder cancer	8.29e-06	4.46e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—HRAS—gallbladder cancer	8.27e-06	4.45e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—ERBB2—gallbladder cancer	8.25e-06	4.44e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—HRAS—gallbladder cancer	8.23e-06	4.43e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—HRAS—gallbladder cancer	8.2e-06	4.41e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—EGFR—gallbladder cancer	8.2e-06	4.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—ERBB2—gallbladder cancer	8.19e-06	4.41e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—gallbladder cancer	8.13e-06	4.38e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—HRAS—gallbladder cancer	8.12e-06	4.37e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—HRAS—gallbladder cancer	8.09e-06	4.36e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—KRAS—gallbladder cancer	8.08e-06	4.35e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—KRAS—gallbladder cancer	8.08e-06	4.35e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—KRAS—gallbladder cancer	8.06e-06	4.34e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—HRAS—gallbladder cancer	8.03e-06	4.32e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—NRAS—gallbladder cancer	7.97e-06	4.29e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—NRAS—gallbladder cancer	7.96e-06	4.29e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—gallbladder cancer	7.96e-06	4.29e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—ERBB2—gallbladder cancer	7.95e-06	4.28e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—KRAS—gallbladder cancer	7.93e-06	4.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—HRAS—gallbladder cancer	7.93e-06	4.27e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—HRAS—gallbladder cancer	7.9e-06	4.26e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—gallbladder cancer	7.89e-06	4.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—HRAS—gallbladder cancer	7.82e-06	4.21e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—KRAS—gallbladder cancer	7.74e-06	4.17e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—KRAS—gallbladder cancer	7.68e-06	4.14e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—gallbladder cancer	7.64e-06	4.11e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—HRAS—gallbladder cancer	7.61e-06	4.1e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—ERBB2—gallbladder cancer	7.59e-06	4.08e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB4—gallbladder cancer	7.57e-06	4.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—ERBB2—gallbladder cancer	7.56e-06	4.07e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—gallbladder cancer	7.56e-06	4.07e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—HRAS—gallbladder cancer	7.55e-06	4.06e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—NRAS—gallbladder cancer	7.55e-06	4.06e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NRAS—gallbladder cancer	7.46e-06	4.02e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—HRAS—gallbladder cancer	7.44e-06	4.01e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB3—gallbladder cancer	7.39e-06	3.98e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—BCL2—gallbladder cancer	7.38e-06	3.97e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NRAS—gallbladder cancer	7.36e-06	3.96e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—HRAS—gallbladder cancer	7.31e-06	3.93e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—gallbladder cancer	7.26e-06	3.91e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—gallbladder cancer	7.25e-06	3.91e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ERBB2—gallbladder cancer	7.17e-06	3.86e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KRAS—gallbladder cancer	7.14e-06	3.84e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—gallbladder cancer	7.05e-06	3.79e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NRAS—gallbladder cancer	6.97e-06	3.75e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—gallbladder cancer	6.88e-06	3.7e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—gallbladder cancer	6.87e-06	3.7e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—gallbladder cancer	6.87e-06	3.7e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—KRAS—gallbladder cancer	6.86e-06	3.69e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KRAS—gallbladder cancer	6.85e-06	3.69e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—gallbladder cancer	6.85e-06	3.69e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NRAS—gallbladder cancer	6.82e-06	3.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—NRAS—gallbladder cancer	6.82e-06	3.67e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—NRAS—gallbladder cancer	6.8e-06	3.66e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—gallbladder cancer	6.79e-06	3.66e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ERBB2—gallbladder cancer	6.77e-06	3.65e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—gallbladder cancer	6.74e-06	3.63e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—gallbladder cancer	6.71e-06	3.61e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NRAS—gallbladder cancer	6.66e-06	3.58e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NRAS—gallbladder cancer	6.63e-06	3.57e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—ERBB2—gallbladder cancer	6.62e-06	3.56e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—gallbladder cancer	6.58e-06	3.54e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NRAS—gallbladder cancer	6.57e-06	3.54e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—NRAS—gallbladder cancer	6.55e-06	3.53e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB3—gallbladder cancer	6.55e-06	3.52e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—BCL2—gallbladder cancer	6.53e-06	3.52e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—gallbladder cancer	6.53e-06	3.52e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KRAS—gallbladder cancer	6.49e-06	3.5e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KRAS—gallbladder cancer	6.42e-06	3.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ERBB2—gallbladder cancer	6.41e-06	3.45e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ERBB2—gallbladder cancer	6.35e-06	3.42e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—gallbladder cancer	6.35e-06	3.42e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—KRAS—gallbladder cancer	6.33e-06	3.41e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NRAS—gallbladder cancer	6.31e-06	3.4e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NRAS—gallbladder cancer	6.28e-06	3.38e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NRAS—gallbladder cancer	6.23e-06	3.35e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—gallbladder cancer	6.21e-06	3.35e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—gallbladder cancer	6.21e-06	3.34e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—gallbladder cancer	6.19e-06	3.33e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—gallbladder cancer	6.07e-06	3.27e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—gallbladder cancer	6.06e-06	3.26e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NRAS—gallbladder cancer	6.05e-06	3.26e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—gallbladder cancer	6.04e-06	3.25e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KRAS—gallbladder cancer	6e-06	3.23e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—gallbladder cancer	5.99e-06	3.23e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—gallbladder cancer	5.97e-06	3.21e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KRAS—gallbladder cancer	5.87e-06	3.16e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—KRAS—gallbladder cancer	5.87e-06	3.16e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—ERBB2—gallbladder cancer	5.86e-06	3.16e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KRAS—gallbladder cancer	5.85e-06	3.15e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—gallbladder cancer	5.83e-06	3.14e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—gallbladder cancer	5.83e-06	3.14e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB2—gallbladder cancer	5.78e-06	3.11e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NRAS—gallbladder cancer	5.77e-06	3.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NRAS—gallbladder cancer	5.75e-06	3.1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—gallbladder cancer	5.75e-06	3.1e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—KRAS—gallbladder cancer	5.73e-06	3.08e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—gallbladder cancer	5.72e-06	3.08e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—gallbladder cancer	5.71e-06	3.07e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—gallbladder cancer	5.7e-06	3.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—gallbladder cancer	5.68e-06	3.06e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—gallbladder cancer	5.66e-06	3.05e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—gallbladder cancer	5.66e-06	3.05e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—gallbladder cancer	5.64e-06	3.04e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—gallbladder cancer	5.57e-06	3e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—gallbladder cancer	5.52e-06	2.97e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—gallbladder cancer	5.51e-06	2.97e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—gallbladder cancer	5.46e-06	2.94e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—gallbladder cancer	5.46e-06	2.94e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—gallbladder cancer	5.43e-06	2.92e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—gallbladder cancer	5.4e-06	2.91e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—gallbladder cancer	5.38e-06	2.9e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—gallbladder cancer	5.36e-06	2.89e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—gallbladder cancer	5.36e-06	2.89e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—gallbladder cancer	5.29e-06	2.85e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—gallbladder cancer	5.26e-06	2.83e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—gallbladder cancer	5.24e-06	2.82e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—gallbladder cancer	5.22e-06	2.81e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—gallbladder cancer	5.21e-06	2.8e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—gallbladder cancer	5.15e-06	2.77e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—gallbladder cancer	5.1e-06	2.74e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—gallbladder cancer	5.04e-06	2.71e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—gallbladder cancer	5.03e-06	2.71e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—gallbladder cancer	4.99e-06	2.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—gallbladder cancer	4.99e-06	2.69e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—gallbladder cancer	4.97e-06	2.68e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—gallbladder cancer	4.97e-06	2.68e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—gallbladder cancer	4.97e-06	2.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—gallbladder cancer	4.95e-06	2.66e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—gallbladder cancer	4.88e-06	2.63e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—gallbladder cancer	4.87e-06	2.62e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—gallbladder cancer	4.85e-06	2.61e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—gallbladder cancer	4.83e-06	2.6e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—gallbladder cancer	4.81e-06	2.59e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—gallbladder cancer	4.79e-06	2.58e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—gallbladder cancer	4.7e-06	2.53e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—gallbladder cancer	4.7e-06	2.53e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—gallbladder cancer	4.64e-06	2.5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—gallbladder cancer	4.62e-06	2.49e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—gallbladder cancer	4.59e-06	2.47e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—gallbladder cancer	4.59e-06	2.47e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—gallbladder cancer	4.56e-06	2.45e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—gallbladder cancer	4.46e-06	2.4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—gallbladder cancer	4.45e-06	2.39e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—gallbladder cancer	4.44e-06	2.39e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—gallbladder cancer	4.43e-06	2.38e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—gallbladder cancer	4.41e-06	2.38e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—gallbladder cancer	4.4e-06	2.37e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—gallbladder cancer	4.4e-06	2.37e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—gallbladder cancer	4.34e-06	2.33e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—gallbladder cancer	4.3e-06	2.32e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—gallbladder cancer	4.24e-06	2.28e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—gallbladder cancer	4.22e-06	2.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—gallbladder cancer	4.21e-06	2.27e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—gallbladder cancer	4.2e-06	2.26e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—gallbladder cancer	4.16e-06	2.24e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—gallbladder cancer	4.1e-06	2.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—gallbladder cancer	4.08e-06	2.2e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—gallbladder cancer	4.06e-06	2.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—gallbladder cancer	4.03e-06	2.17e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—gallbladder cancer	4e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—gallbladder cancer	3.99e-06	2.15e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—gallbladder cancer	3.94e-06	2.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—gallbladder cancer	3.92e-06	2.11e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—gallbladder cancer	3.86e-06	2.08e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—gallbladder cancer	3.84e-06	2.07e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—gallbladder cancer	3.78e-06	2.04e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—gallbladder cancer	3.77e-06	2.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—gallbladder cancer	3.73e-06	2.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—gallbladder cancer	3.72e-06	2e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—gallbladder cancer	3.7e-06	1.99e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—gallbladder cancer	3.69e-06	1.98e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—gallbladder cancer	3.67e-06	1.98e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—gallbladder cancer	3.65e-06	1.96e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—gallbladder cancer	3.57e-06	1.92e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—gallbladder cancer	3.53e-06	1.9e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—gallbladder cancer	3.53e-06	1.9e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—gallbladder cancer	3.51e-06	1.89e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—gallbladder cancer	3.47e-06	1.87e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—gallbladder cancer	3.36e-06	1.81e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—gallbladder cancer	3.29e-06	1.77e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—gallbladder cancer	3.26e-06	1.76e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—gallbladder cancer	3.24e-06	1.74e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—gallbladder cancer	3.22e-06	1.73e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—gallbladder cancer	3.21e-06	1.73e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—gallbladder cancer	3.15e-06	1.7e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—gallbladder cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—gallbladder cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—gallbladder cancer	3.1e-06	1.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—gallbladder cancer	3.08e-06	1.66e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—gallbladder cancer	3.04e-06	1.63e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—gallbladder cancer	2.98e-06	1.61e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—gallbladder cancer	2.95e-06	1.59e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—gallbladder cancer	2.85e-06	1.53e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—gallbladder cancer	2.7e-06	1.45e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—gallbladder cancer	2.69e-06	1.45e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—gallbladder cancer	2.58e-06	1.39e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—gallbladder cancer	2.39e-06	1.29e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—gallbladder cancer	2.28e-06	1.23e-05	CbGpPWpGaD
